Abbvie Stock News

AbbVie (NYSE:ABBV) had its price objective boosted by stock analysts at Truist from $118.00 to $135.00 in a research note issued on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock. Truists price objective would suggest a potential upside of 13.77% from the stocks previous close. ABBV has been the []

Appleton Partners Inc. MA raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,555 shares of the companys stock after acquiring an additional 2,909 shares during the period. Appleton Partners []

Pacific Wealth Strategies Group Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,402 shares of the companys stock after acquiring an additional 147 shares during the quarter. []

WESPAC Advisors SoCal LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 26.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,626 shares of the company’s stock after selling 22,941 shares during the quarter. AbbVie makes up 2.3% […]

Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 11.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 19,571 shares of the companys stock after purchasing an additional 1,945 shares during the quarter. AbbVie makes up 1.1% of Investors Asset Management of Georgia Inc. GA ADVs []

DUBLIN--(BUSINESS WIRE)--The "Cellulitis - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com''s offering. This clinical trial report provides an overview of the Cellulitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cellulitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials

AbbVie (NYSE:ABBV) had its price target boosted by Truist from $118.00 to $135.00 in a research note released on Wednesday, The Fly reports. Truist currently has a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Barclays increased their target price on shares of AbbVie from []

Global Small Molecule Sterile Injectable Drugs Market Overview: A brilliant Small Molecule Sterile Injectable Drugs Market research report brings into focus the key market dynamics of the sector. This market study also analyzes the market status, market share, growth rate, future

Bilibili Inc. (BILI) with the stream of 4.85% also noticed, India AbbVie Inc. (ABBV) encountered a rapid change of -0.03% in the last hour of Wednesdays trading session. Bilibili Inc. The post Heres What to Focus on: Bilibili Inc. (NASDAQ:BILI), AbbVie Inc. (NYSE:ABBV) appeared first on Stocks Equity .

Stolper Co increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 17,977 shares of the companys stock after acquiring an additional 197 shares during the period. Stolper Cos holdings in AbbVie were worth $1,939,000 at the end of the most recent quarter. Other []

Asset Management Corp IL ADV lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 23.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 24,969 shares of the companys stock after acquiring an additional 4,750 shares during the period. AbbVie accounts for about 1.4% of Asset Management Corp IL ADVs investment portfolio, making the []

Butensky & Cohen Financial Security Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,108 shares of the company’s stock after purchasing an additional 627 shares during the period. […]

Related Stocks: FREL , TEAM , CRWD , DE , SE , IWD , CTLT , SYK , BILL , OKE , APD , ABBV , SCHH , GSHD , FIVN , CBRE , STL , EMR ,

The trading price of AbbVie Inc. (NYSE:ABBV) closed higher on Tuesday, November 23, closing at $118.88, 2.79% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy